AbbVie's Mavyret Approved for Hep C in Pediatric and Adolescent Patients 0 01.05.2019 03:00 Feedity.com The FDA gave the nod to AbbVie’s Mavyret for all six strains of hepatitis C in children ages 12 to 17 years. The drug was approved for adults 18 years or older in 2017. Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа
